Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

Gut

Volumn 56, Issue 4, 2007, Pages 509-517

  Van Den Brande, Jan M H ^a   Koehler, Tamara C ^a   Zelinkova, Zuzana ^a   Bennink, Roelof J ^a   Te Velde, Anje A ^a   Ten Cate, Fibo J W ^a   Van Deventer, Sander J H ^a   Peppelenbosch, Maikel P ^b   Hommes, Daniët W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; LIPOCORTIN 5; MERCAPTOPURINE; METHOTREXATE; TECHNETIUM 99M; TIOGUANINE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNSPECIFIED SIDE EFFECT;

ADULT; ANIMALS; ANNEXIN A5; ANTIBODIES, MONOCLONAL; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; COLITIS; CROHN DISEASE; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34147211616     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.105379     Document Type: Article

References (41)

1. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-57.
2. van Deventer SJ. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999;13(Suppl 4):3-8.
3. Black RA, Rauch CT, Kozlosky CT, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-33.
4. Moss ML, Jin SL, Becherer JD, et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 1997;72:127-9.
5. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
6. Breese E, MacDonald TT. TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol 1995;371B:821-4.
7. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
8. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
9. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
10. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
11. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
12. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
13. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
14. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
15. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124: 1774-85.
16. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376-92.
17. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-90.
18. Ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
19. Hofstra L, Dumont EA, Thimister PW, et al. In vivo detection of apoptosis in an intracardiac tumor. JAMA 2001;285:1841-2.
20. Dumont EA, Reutelingsperger CP, Smits JF, et al. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 2001;7:1352-5.
21. Green AM, Steinmetz ND. Monitoring apoptosis in real time. Cancer J 2002;8:82-92.
22. Ten Hove T, Corbaz A, Amitai H, et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001;121:1372-9.
23. van Montfrans C, Rodriguez Pena MS, Pronk I, et al. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology 2002;123:1865-76.
24. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
25. Habraken JB, de Bruin K, Shehata M, et al. Evaluation of high-resolution pinhole SPEC using a small rotating animal. J Nucl Med 2001;42:1863-9.
26. Bennink RJ, Hamann J, de Bruin K, et al. Dedicated pinhole SPECT of intestinal neutrophil recruitment in a mouse model of dextran sulfate sodium-induced colitis. J Nucl Med 2005;46:526-31.
27. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45.
28. Belhocine T, Steinmetz N, Li C, et al. The imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility. Technol Cancer Res Treat 2004;3:23-32.
29. Blankenberg FG, Naumovski L, Tait JF, et al. Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V. J Nucl Med 2001;42:309-16.
30. Ohtsuki K, Akashi K, Aoka Y, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med 1999;26:1251-8.
31. Ogura Y, Krams SM, Martinez OM, et al. Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology 2000;214:795-800.
32. Post AM, Kotsikis PD, Tait JF, et al. Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J Nucl Med 2002;43:1359-65.
33. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000;356:209-12.
34. Kemerink GJ, Liem IH, Hofstra L, et al. Patient dosimetry of intravenously administered 99mTc-annexin V. J Nucl Med 2001;42:382-7.
35. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002;8:2766-74.
36. Yang DJ, Azhdarinia A, Wu P, et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother Radiopharm 2001;16:73-83.
37. Kartachova M, Haas RL, Olmos RA, et al. In vivo imaging of apoptosis by 99mTc-annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol 2004;72:333-9.
38. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004;53:70-7.
39. Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 1999;40:184-91.
40. Shen C, Maerten P, Geboes K, et al. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005;115:250-9.
41. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005;21:251-8.